These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36370336)

  • 21. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
    Worm M; Thyssen JP; Schliemann S; Bauer A; Shi VY; Ehst B; Tillmann S; Korn S; Resen K; Agner T
    Br J Dermatol; 2022 Jul; 187(1):42-51. PubMed ID: 35084738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis.
    Naegeli AN; Flood E; Tucker J; Devlen J; Edson-Heredia E
    Int J Dermatol; 2015 Jun; 54(6):715-22. PubMed ID: 25515935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus.
    Vernon MK; Swett LL; Speck RM; Munera C; Spencer RH; Wen W; Menzaghi F
    J Patient Rep Outcomes; 2021 Dec; 5(1):134. PubMed ID: 34952964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cannabis-Containing Cream for CKD-Associated Pruritus: A Double-Blind, Placebo Controlled Trial.
    Anumas S; Kuropakornpong P; Chakkavittumrong P; Tasanarong A; Pattharanitima P
    Kidney Med; 2024 Oct; 6(10):100894. PubMed ID: 39328960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
    Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
    J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
    Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
    J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
    Jalili A; Lebwohl M; Stein Gold L; Andersen SB; Jensen KL; Pink AE; Segaert S; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):709-717. PubMed ID: 30520168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis.
    Pixley JN; Schaetzle T; Feldman SR
    Ann Pharmacother; 2023 Aug; 57(8):966-969. PubMed ID: 36420929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
    JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial.
    Pariser DM; Bagel J; Lebwohl M; Yosipovitch G; Chien E; Spellman MC
    J Am Acad Dermatol; 2020 Jun; 82(6):1314-1320. PubMed ID: 32007513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
    Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
    EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.
    Yosipovitch G; Reich A; Steinhoff M; Beselin A; Kent T; Dossenbach M; Berggren L; Henneges C; Luger T
    Dermatol Ther (Heidelb); 2018 Dec; 8(4):621-637. PubMed ID: 30465321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
    Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study.
    Gooderham M; Kircik L; Zirwas M; Lee M; Kempers S; Draelos Z; Ferris L; Jones T; Saint-Cyr Proulx E; Bissonnette R; Bhatia N; Koppel R; Guenthner S; Eads K; Welgus H; Merritt C; Elias M; Navale L; Higham R; Droege M; Berk D
    J Drugs Dermatol; 2023 Feb; 22(2):139-147. PubMed ID: 36745371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.
    Kwatra SG; Yosipovitch G; Ständer S; Guillemin I; Msihid J; Bansal A; Makhija M; Wiggins S; Zahn J; Thomas RB; Bahloul D
    J Eur Acad Dermatol Venereol; 2024 Oct; 38(10):1965-1972. PubMed ID: 38785405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
    Landis MN; Smith SR; Berstein G; Fetterly G; Ghosh P; Feng G; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Beebe JS; Tarabar S
    Br J Dermatol; 2023 Jul; 189(1):33-41. PubMed ID: 36972293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
    Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
    Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.